SAN DIEGO, Aug. 5 (HSMN NewsFeed) — Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company’s Phase 2 trial of CERE-120 for Parkinson’s disease. The…
Biopharmaceuticals, Neurology
Ceregene, CERE-120, Parkinson’s disease

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients”
Leave a Comment